Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.
Contact

News & Events:

Revealing the true targets for next generation immunotherapies.
Learn More

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Date: April 23, 2026 |
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, UK and MONTREAL, CANADA, 23 April 2026 – Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that it has received […]
Read More

Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield

Date: April 13, 2026 |
CAMBRIDGE, UK and MONTREAL, CANADA, 13 April 2026 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies […]
Read More

Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy

Date: September 18, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 18 September 2025 – Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Date: July 10, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025 – Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC

Date: May 27, 2025 |
Further Validates CryptigensTM as Actionable Targets for Cancer Immunotherapy Montreal, Quebec, & Cambridge, UK, 27 May 2025 – Epitopea, a […]
Read More

Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens

Date: February 19, 2025 |
Montreal, Quebec and Cambridge, UK February 19, 2025: Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces […]
Read More

Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer 

Date: February 7, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 7 February 2025 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea and Genevant Sciences Announce Collaboration Agreement

Date: December 19, 2024 |
CAMBRIDGE, UK, MONTREAL, CANADA, VANCOUVER, CANADA, and BASEL, SWITZERLAND — December 19, 2024 (GLOBE NEWSWIRE) — Epitopea, a transatlantic cancer […]
Read More

Epitopea Closes USD $31 million Pre-Series A Financing

Date: October 24, 2024 |
Proceeds support strategic development and clinical entry of lead Cryptigen immunotherapeutics CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024 - […]
Read More

CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Platform Enabling the Development of RNA-based Immunotherapies

Date: September 26, 2024 |
Montreal, Quebec, 26 September 2024 – Epitopea, a transatlantic cancer immunotherapy company, and CQDM are proud to announce the launch […]
Read More
1 2
Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by FDM Digital